Want to see CGEM full AI Analyst Report?
Cullinan Management (CGEM) AI Stock Analysis
Cullinan Management
(NASDAQ:CGEM)
CGEM’s score is held down primarily by weak financial performance (no meaningful revenue, sizable losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting these pressures, recent corporate events are constructive—strong Phase 3 zipalertinib results and progress toward an NDA provide meaningful upside potential—but the current fundamentals and trend keep the overall score below average.
Cullinan Management (CGEM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $767.61M
- Dividend Yield
- ―
- Average Volume (3M)
- 932.84K
- Price to Earnings (P/E)
- -3.7
- Beta (1Y)
- 0.89
- Revenue Growth
- ―
- EPS Growth
- 3.56%
- Country
- US
- Employees
- 109
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Cullinan Management Business Overview & Revenue Model
Company Description
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune disease...
Cullinan Management Financial Statement Overview
Summary
Overall early-stage biotech profile: effectively no recurring revenue, large and persistent net losses (TTM net loss ~-$205M) and heavy ongoing cash burn (TTM FCF ~-$159M). Balance sheet leverage is low (total debt ~ $2.1M), but equity has declined materially over recent periods, underscoring reliance on external funding.
Income Statement
18Very NegativeBalance Sheet
62PositiveCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 18.94M |
| Gross Profit | 0 | 0 | -306.00K | -310.00K | 0 | 18.94M |
| EBITDA | -208.41M | -219.57M | -167.15M | -190.34M | -132.04M | -67.43M |
| Net Income | -204.69M | -219.88M | -167.38M | -153.16M | 111.21M | -65.57M |
Balance Sheet | ||||||
| Total Assets | 363.79M | 448.37M | 621.82M | 484.18M | 561.12M | 437.19M |
| Cash, Cash Equivalents and Short-Term Investments | 334.54M | 377.90M | 398.98M | 467.07M | 467.29M | 290.47M |
| Total Debt | 2.07M | 2.68M | 2.15M | 3.59M | 5.19M | 0 |
| Total Liabilities | 42.03M | 39.64M | 31.50M | 30.29M | 26.09M | 11.81M |
| Stockholders Equity | 321.75M | 408.73M | 590.33M | 453.70M | 535.03M | 424.97M |
Cash Flow | ||||||
| Free Cash Flow | -159.30M | -175.80M | -145.30M | -134.48M | -127.80M | -44.02M |
| Operating Cash Flow | -159.25M | -175.75M | -145.30M | -134.28M | -126.66M | -43.43M |
| Investing Cash Flow | 162.88M | 179.99M | -136.31M | 35.81M | 248.97M | -333.77M |
| Financing Cash Flow | 2.19M | 1.09M | 266.19M | 40.75M | -25.93M | 268.78M |
Cullinan Management Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CGEM, the sentiment is Negative. The current price of 12.49 is below the 20-day moving average (MA) of 14.61, below the 50-day MA of 17.44, and below the 200-day MA of 15.86, indicating a bearish trend. The MACD of -0.64 indicates Negative momentum. The RSI at 33.89 is Neutral, neither overbought nor oversold. The STOCH value of 46.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CGEM.
Cullinan Management Risk Analysis
Cullinan Management disclosed 80 risk factors in its most recent earnings report. Cullinan Management reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskCullinan Management Peers Comparison
Overall Rating
JANX56Neutral
TYRA52Neutral- CGEM49Neutral
KURA46Neutral
GLUE44Neutral
IMTX42Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JANX | 56Neutral | $1.09B | -11.02 | -10.79% | ― | 5366.97% | 8.50% |
| TYRA | 52Neutral | $1.47B | -8.97 | -46.39% | ― | ― | -33.90% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CGEM | 49Neutral | $1.01B | -3.71 | -52.89% | ― | ― | 3.56% |
| KURA | 46Neutral | $878.93M | -2.26 | -207.18% | ― | -7.27% | -48.89% |
| GLUE | 44Neutral | $888.11M | -4.96 | -43.31% | ― | -83.86% | -646.52% |
| IMTX | 42Neutral | $1.06B | -3.86 | -47.04% | ― | -65.40% | -164.71% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CGEM | Cullinan Therapeutics Inc | 12.49 | 5.30 | 73.71% | |
| KURA | Kura Oncology | 7.61 | -2.25 | -22.82% | |
| IMTX | Immatics N.V. | 6.91 | -2.14 | -23.65% | |
| JANX | Janux Therapeutics, Inc. | 18.18 | -8.30 | -31.34% | |
| GLUE | Monte Rosa Therapeutics, Inc. | 10.82 | -1.49 | -12.10% | |
| TYRA | Tyra Bioscience, Inc | 21.52 | 7.20 | 50.31% |
Cullinan Management Corporate Events
Cullinan Shares Updated CLN-049 Phase 1 AML/MDS Data
PositiveOn November 4, 2026, Cullinan shared updated Phase 1 dose-escalation data for CLN-049 in 87 patients with relapsed or refractory AML or MDS. A two-step-up regimen lowered CRS incidence to 26% from 36% and limited observed cases to Grade 1 or 2, while...
Cullinan Management Advances NDA for Zipalertinib Combination
PositiveOn October 1, 2026, Cullinan Therapeutics announced it had initiated a New Drug Application submission to the U.S. Food and Drug Administration for zipalertinib combined with platinum-based chemotherapy. The filing seeks approval for first-line treat...
Cullinan Management Highlights Q4 T Cell Engager Milestones
PositiveOn September 24, 2026, Cullinan Therapeutics outlined key fourth-quarter 2026 milestones across its immunology and oncology T cell engager pipeline, signalling a data-rich period that could shape perceptions of its clinical strategy. The company plan...
Cullinan Highlights Positive Phase 3 Lung Cancer Results
PositiveOn September 13, 2026, Cullinan Therapeutics and its partners Taiho Oncology and Taiho Pharmaceutical reported Phase 3 data from the global REZILIENT3 trial in first-line treatment of advanced non-small cell lung cancer with EGFR exon 20 insertion mu...
Cullinan Reports Positive Phase 3 Zipalertinib Lung Cancer Data
PositiveOn August 12, 2026, Cullinan Therapeutics and Taiho announced that the global Phase 3 REZILIENT3 trial of zipalertinib plus platinum-based chemotherapy in first-line treatment of EGFR exon 20 insertion-mutated non-small cell lung cancer met its prima...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 05, 2026